Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors

Cancer

Volumn 116, Issue 22, 2010, Pages 5126-5137

  Blay, Jean Yves ^a   Von Mehren, Margaret ^b   Blackstein, Martin E ^c  

^a UNIVERSITÉ LYON 1   (France)

^b FOX CHASE CANCER CENTER   (United States)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

gastrointestinal; imatinib; kinases; practice guideline; protein tyrosine; stromal; sunitinib; tumors

Indexed keywords

IMATINIB; MASITINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; UNCLASSIFIED DRUG;

AGED; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; CLINICAL TRIAL; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; UNSPECIFIED SIDE EFFECT;

FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; NEOPLASM STAGING; PIPERAZINES; PRACTICE GUIDELINES AS TOPIC; PYRIMIDINES; RECURRENCE;

EID: 78449266238     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25267     Document Type: Review

References (67)

1. Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)-update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2007; 5 (suppl 2): S1-S29.
2. Miettinen M, Lasota J,. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006; 130: 1466-1478.
3. Miettinen M, Lasota J,. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006; 23: 70-83.
4. Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998; 152: 1259-1269.
5. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002; 33: 459-465.
6. Blay P, Astudillo A, Buesa JM, et al. Protein kinase C theta is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias. Clin Cancer Res. 2004; 10: 4089-4095.
7. Espinosa I, Lee CH, Kim MK, et al. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol. 2008; 32: 210-218.
8. Joensuu H,. Gastrointestinal stromal tumor (GIST). Ann Oncol. 2006; 17 (suppl 10): x280-x286.
9. Tran T, Davila JA, El Serag HB,. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1458 cases from 1992 to 2000. Am J Gastroenterol. 2005; 100: 162-168.
10. Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer. 2005; 103: 821-829.
11. Tryggvason G, Gislason HG, Magnusson MK, et al. Gastrointestinal stromal tumors in Iceland, 1990-2003: the Icelandic GIST Study, a population-based incidence and pathologic risk stratification study. Int J Cancer. 2005; 117: 289-293.
12. Blackstein ME, Blay JY, Corless C, et al. Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment. Can J Gastroenterol. 2006; 20: 157-163.
13. Casali PG, Jost L, Reichardt P, et al. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009; 20 (suppl 4): 64-67.
14. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology for Soft Tissue Sarcoma. Version 2. Fort Washington, Pa: National Comprehensive Cancer Network; 2009.
15. Montemurro M, Dirnhofer S, Borner M, Burkhard R, Demartines N, Furrer M,. Diagnosis and treatment of GIST in Switzerland [guidelines]. Schwiz Med Forum. 2008; 8: 416-430.
16. Nishida T, Hirota S, Yanagisawa A, et al. Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version. Int J Clin Oncol. 2008; 13: 416-430.
17. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998; 279: 577-580.
18. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003; 299: 708-710.
19. Antonescu CR,. Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas. Mod Pathol. 2008; 21 (suppl 2): S31-S36.
20. Agaram NP, Wong GC, Guo T, et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer. 2008; 47: 853-859.
21. Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000; 96: 925-932.
22. Miettinen M, Sarlomo-Rikala M, Lasota J,. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol. 1999; 30: 1213-1220.
23. Clary BM, Dematteo RP, Lewis JJ, et al. Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison. Ann Surg Oncol. 2001; 8: 290-299.
24. Miettinen M, Sobin LH, Lasota J,. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005; 29: 52-68.
25. Lasota J, Miettinen M,. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology. 2008; 53: 245-266.
26. Hassan I, You YN, Shyyan R, et al. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann Surg Oncol. 2008; 15: 52-59.
27. Singer S, Rubin BP, Lux ML, et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol. 2002; 20: 3898-3905.
28. Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009; 373: 1097-1104.
29. Dematteo RP, Owzar K, Antonescu CR, et al. Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: the U.S. Intergroup phase II trial ACOSOG Z9000 [abstract]. Paper presented at: 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, Fla. Abstract 8.
30. Zhan WH,; China Gastrointestinal Cooperative Group. Efficacy and safety of adjuvant post-surgical therapy with imatinib in patients with high risk of relapsing GIST [abstract]. J Clin Oncol. 2007; 25 (18S; June 20 suppl). Abstract 10045.
31. European Organisation for Research and Treatment of Cancer. EORTC 62024 study protocol. Phase III randomized study of adjuvant imatinib mesylate versus observation only in patients with completely resected localized gastrointestinal stromal tumor at intermediate-or high-risk of relapse. Available at:. Accessed September 2, 2009.
32. Scandinavian Sarcoma Group. SSGXVIII/AIO study protocol. Study comparing 12 months versus 36 months of imatinib in the treatment of gastrointestinal stromal tumor (GIST). Available at:. Accessed September 2, 2009.
33. Novartis Pharmaceuticals Corporation: Gleevec (imatinib) Prescribing Information., East Hanover, NJ,; Novartis Pharmaceuticals Corporation; 2008.
34. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347: 472-480.
35. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008; 26: 620-625.
36. Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at 2 dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008; 26: 626-632.
37. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004; 364: 1127-1134.
38. Casali PG, Verweij J, Kotasek D, et al. Imatinib mesylate in advanced gastrointestinal stromal tumors (GIST): survival analysis of the intergroup EORTC/ISG/AGITG randomized trial in 946 patients. Eur J Cancer. 2005; 3 (suppl): 201. Abstract 711.
39. Van Glabbeke MM, Owzar K, Rankin C, Simes J, Crowley J,; GIST Meta-Analysis Group (MetaGIST). Comparison of 2 doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): a meta-analysis based on 1640 patients (pts) [abstract]. J Clin Oncol. 2007; 25 (18S). Abstract 10004.
40. Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol. 2007; 14: 14-24.
41. Bonvalot S, Eldweny H, Pechoux CL, et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol. 2006; 13: 1596-1603.
42. Dematteo RP, Maki RG, Singer S, et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg. 2007; 245: 347-352.
43. Gronchi A, Fiore M, Miselli F, et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg. 2007; 245: 341-346.
44. Haller F, Detken S, Schulten HJ, et al. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol. 2007; 14: 526-532.
45. Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006; 24: 2325-2331.
46. Rutkowski P, Nowecki Z, Nyckowski P, et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol. 2006; 93: 304-311.
47. Hopkins TG, Marples M, Stark D,. Sunitinib in the management of gastrointestinal stromal tumours (GISTs). Eur J Surg Oncol. 2008; 34: 844-850.
48. Rock EP, Goodman V, Jiang JX, et al. Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist. 2007; 12: 107-113.
49. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006; 368: 1329-1338.
50. George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer. 2009; 45: 1959-1968.
51. Liegl B, Fletcher JA, Corless CL, et al. Correlation between KIT mutations and sunitinib (SU) resistance in GIST [abstract]. Paper presented at: 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, Fla. Abstract 92.
52. Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008; 26: 5352-5359.
53. Pfizer Pharmaceuticals,. Sutent (sunitinib) Prescribing Information. New York: Pfizer Pharmaceuticals; 2008.
54. Prenen H, Guetens G, de Boeck G, et al. Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. Pharmacology. 2006; 77: 11-16.
55. Demetri GD, Casali PG, Blay JY, et al. A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res. 2009; 18: 5902-5909.
56. Novartis Pharmaceuticals. Efficacy and safety of AMN107 compared with current treatment options in patients with GIST who have failed both imatinib and sunitinib (ENEST). Available at:. Accessed September 3, 2009.
57. Novartis Pharmaceuticals. Phase III, open-label study of nilotinib versus imatinib in GIST patients (ENESTg1). Available at:. Accessed September 3, 2009.
58. Soria JC, Massard C, Magne N, et al. Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers. Eur J Cancer. 2009; 45: 2333-2341.
59. Le Cesne A, Blay J, Bui NB, et al. Masatinib mesylate in imatinib-naive locally advanced or metastatic gastrointestinal stromal tumor (GIST): results of the French Sarcoma Group phase II trial [abstract]. J Clin Oncol. 2009; 27 (15S). Abstract 10507.
60. Choi H, Charnsangavej C, de Castro FS, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol. 2004; 183: 1619-1628.
61. Therasse P, Eisenhauer EA, Verweij J,. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer. 2006; 42: 1031-1039.
62. Choi SM, Kim MC, Jung GJ, et al. Laparoscopic wedge resection for gastric GIST: long-term follow-up results. Eur J Surg Oncol. 2007; 33: 444-447.
63. Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol. 2007; 25: 1760-1764.
64. Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol. 2009; 27: 3141-3147.
65. Adenis A, Cassier P, Bui B, et al. Does interruption of imatinib (IM) in responding patients after 3 years of treatment influence outcome of patients with advanced GIST included in the BFR14 trial [abstract]? J Clin Oncol. 2008; 26 (May 20 suppl). Abstract 10522.
66. Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol. 2007; 25: 1107-1113.
67. Duffaud F, Ray-Coquard I, Bui B, et al. Time to secondary resistance (TSR) after interruption of imatinib: updated results of the prospective French Sarcoma Group randomized phase III trial on long-term survival [abstract]. J Clin Oncol. 2009; 27 (15S). Abstract 10508.